171 related articles for article (PubMed ID: 10856268)
1. In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor.
Azizi M; Massien C; Michaud A; Corvol P
Hypertension; 2000 Jun; 35(6):1226-31. PubMed ID: 10856268
[TBL] [Abstract][Full Text] [Related]
2. Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake.
Azizi M; Lamarre-Cliche M; Labatide-Alanore A; Bissery A; Guyene TT; Ménard J
J Am Soc Nephrol; 2002 Oct; 13(10):2454-63. PubMed ID: 12239234
[TBL] [Abstract][Full Text] [Related]
3. Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat.
Kubota E; Dean RG; Hubner RA; Casley DJ; Johnston CI; Burrell LM
Clin Sci (Lond); 2003 Sep; 105(3):339-45. PubMed ID: 12741953
[TBL] [Abstract][Full Text] [Related]
4. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats.
Cao Z; Burrell LM; Tikkanen I; Bonnet F; Cooper ME; Gilbert RE
Kidney Int; 2001 Aug; 60(2):715-21. PubMed ID: 11473654
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
Raasch W; Dominiak P; Dendorfer A
J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
[TBL] [Abstract][Full Text] [Related]
6. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.
Regamey F; Maillard M; Nussberger J; Brunner HR; Burnier M
Hypertension; 2002 Sep; 40(3):266-72. PubMed ID: 12215465
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406.
Sulpizio AC; Pullen MA; Edwards RM; Louttit JB; West R; Brooks DP
J Pharmacol Exp Ther; 2005 Dec; 315(3):1306-13. PubMed ID: 16144980
[TBL] [Abstract][Full Text] [Related]
8. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
Pu Q; Larouche I; Schiffrin EL
Am J Hypertens; 2003 Nov; 16(11 Pt 1):931-7. PubMed ID: 14573331
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
[TBL] [Abstract][Full Text] [Related]
10. Role of Angiotensin-converting enzyme and neutral endopeptidase in flow-dependent remodeling.
Korshunov VA; Massett MP; Carey RM; Berk BC
J Vasc Res; 2004; 41(2):148-56. PubMed ID: 15004434
[TBL] [Abstract][Full Text] [Related]
11. Vasopeptidase inhibition in a canine model of exercise-induced left ventricular dysfunction.
Holzgrefe HH; Arthur SR; Powell JR
Clin Exp Pharmacol Physiol; 2002 Aug; 29(8):696-703. PubMed ID: 12100002
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
[TBL] [Abstract][Full Text] [Related]
13. Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I.
Michaud A; Williams TA; Chauvet MT; Corvol P
Mol Pharmacol; 1997 Jun; 51(6):1070-6. PubMed ID: 9187274
[TBL] [Abstract][Full Text] [Related]
14. The cardiovascular actions of omapatrilat in spontaneously hypertensive rats.
Dong Y; Zhou H; Shaffer E; Atamas N; Liao WC; Wei C
Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S1-5. PubMed ID: 11716799
[TBL] [Abstract][Full Text] [Related]
15. Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension.
Maniu CV; Meyer DM; Redfield MM
Hypertension; 2002 Oct; 40(4):528-34. PubMed ID: 12364358
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.
Liao WC; Vesterqvist O; Delaney C; Jemal M; Ferreira I; Ford N; Swanson B; Uderman H
Br J Clin Pharmacol; 2003 Oct; 56(4):395-406. PubMed ID: 12968984
[TBL] [Abstract][Full Text] [Related]
17. Chronic vasopeptidase inhibition restores endothelin-converting enzyme activity and normalizes endothelin levels in salt-induced hypertension.
Quaschning T; d'Uscio LV; Shaw S; Viswambharan H; Ruschitzka FT; Lüscher TF
Nephrol Dial Transplant; 2001 Jun; 16(6):1176-82. PubMed ID: 11390717
[TBL] [Abstract][Full Text] [Related]
18. Vasopeptidase inhibition: a new concept in blood pressure management.
Burnett JC
J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline.
Azizi M; Junot C; Ezan E; Ménard J
Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1066-9. PubMed ID: 11903317
[TBL] [Abstract][Full Text] [Related]
20. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.
Jandeleit-Dahm K; Lassila M; Davis BJ; Candido R; Johnston CI; Allen TJ; Burrell LM; Cooper ME
J Hypertens; 2005 Nov; 23(11):2071-82. PubMed ID: 16208151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
